Literature DB >> 7194166

Clinical kinetics on intact cisplatin and some related species.

K J Himmelstein, T F Patton, R J Belt, S Taylor, A J Repta, L A Sternson.   

Abstract

Plasma concentrations of cisplatin, total platinum, and total filterable platinum were monitored in 24 patients after either 50 or 100 mg/m2 of cisplatin by rapid intravenous injection. Half the patients at each dose were pretreated with mannitol. Total platinum levels declined in a triphasic fashion with a terminal half-life (t1/2)greater than or equal to 24 hr. Both total filterable platinum and cisplatin levels declined in a monophasic manner and exhibited t1/2 of 0.3 to 0.5 hr. The ratio of cisplatin to total filterable platinum in plasma remained constant (0.6 to 0.8) over the time period (2 hr) during which they could be detected, while the ratio of the plasma levels of cisplatin to total platinum decreased continuously from approximately 0.5 at 5 min to approximately 0.10 at 2 hr. Larger doses of cisplatin resulted in higher plasma levels of all three species monitored, and although the increases appeared somewhat less than proportional to dose, terminal plasma slopes were not dose dependent. Neither mannitol nor dose had an effect on the various species ratios, nor did mannitol appear to affect either plasma levels or terminal plasma decline.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7194166     DOI: 10.1038/clpt.1981.91

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  43 in total

Review 1.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

2.  Experiences with sodium thiosulfate after intracarotid infusion of cisplatin and BCNU for malignant gliomas.

Authors:  R B Vance; J Pittisapu; J P Kapp
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

3.  Theoretical study of the influence of the circadian rhythm of plasma protein binding on cisplatin area under the curve.

Authors:  B Hecquet; M Sucche
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

4.  Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer.

Authors:  Aarif Ahsan; Susan M Hiniker; Susmita G Ramanand; Shyam Nyati; Ashok Hegde; Abigail Helman; Radhika Menawat; Mahaveer S Bhojani; Theodore S Lawrence; Mukesh K Nyati
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

5.  Effect of hyaluronidase on the pharmacokinetics of free and total platinum species after intra-arterial Cisplatin in refractory patients with colorectal liver metastases.

Authors:  D Civalleri; M Esposito; F De Cain; F Decian; N Balletto; G Mondini; L Gogioso; M Viale; M O Vannozzi
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

6.  Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans.

Authors:  C Fournier; P Vennin; B Hecquet
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  In vitro plasma binding of some second generation antitumor platinum complexes.

Authors:  R Momburg; M Bourdeaux; M Sarrazin; F Roux; C Briand
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jan-Mar       Impact factor: 2.441

8.  Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species.

Authors:  F G King; R L Dedrick; F F Farris
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

Review 9.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

10.  Inactivation of cis-diamminedichloroplatinum (II) in blood and protection of its toxicity by sodium thiosulfate in rabbits.

Authors:  Y Iwamoto; T Kawano; M Ishizawa; K Aoki; T Kuroiwa; T Baba
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.